KR20220110221A - 항-oxMIF/항-CD3 이중특이적 항체 구축물 - Google Patents

항-oxMIF/항-CD3 이중특이적 항체 구축물 Download PDF

Info

Publication number
KR20220110221A
KR20220110221A KR1020227020304A KR20227020304A KR20220110221A KR 20220110221 A KR20220110221 A KR 20220110221A KR 1020227020304 A KR1020227020304 A KR 1020227020304A KR 20227020304 A KR20227020304 A KR 20227020304A KR 20220110221 A KR20220110221 A KR 20220110221A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227020304A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 쉬내글
로버트 마이클 티엘
란돌프 커쉬바우머
Original Assignee
온코원 리서치 앤드 디벨롭먼트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코원 리서치 앤드 디벨롭먼트 게엠베하 filed Critical 온코원 리서치 앤드 디벨롭먼트 게엠베하
Publication of KR20220110221A publication Critical patent/KR20220110221A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227020304A 2019-12-06 2020-12-04 항-oxMIF/항-CD3 이중특이적 항체 구축물 Pending KR20220110221A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214037 2019-12-06
EP19214037.4 2019-12-06
PCT/EP2020/084676 WO2021110935A1 (en) 2019-12-06 2020-12-04 Anti-oxMIF/anti-CD3 BISPECIFIC ANTIBODY CONSTRUCTS

Publications (1)

Publication Number Publication Date
KR20220110221A true KR20220110221A (ko) 2022-08-05

Family

ID=68808117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227020304A Pending KR20220110221A (ko) 2019-12-06 2020-12-04 항-oxMIF/항-CD3 이중특이적 항체 구축물

Country Status (8)

Country Link
US (1) US20230045873A1 (https=)
EP (1) EP4069735A1 (https=)
JP (1) JP2023504620A (https=)
KR (1) KR20220110221A (https=)
CN (1) CN115943160A (https=)
AU (1) AU2020397229A1 (https=)
CA (1) CA3161783A1 (https=)
WO (1) WO2021110935A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220521A1 (en) 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
US9958456B2 (en) * 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
RU2639287C2 (ru) * 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3802595A1 (en) 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
TWI899079B (zh) * 2019-05-23 2025-10-01 美商維洛斯生物公司 抗ror1/抗cd3雙特異性結合分子
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子

Also Published As

Publication number Publication date
JP2023504620A (ja) 2023-02-06
AU2020397229A9 (en) 2023-06-29
WO2021110935A1 (en) 2021-06-10
US20230045873A1 (en) 2023-02-16
CN115943160A (zh) 2023-04-07
AU2020397229A1 (en) 2022-06-30
CA3161783A1 (en) 2021-06-10
EP4069735A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
US11021694B2 (en) SIRP-α immunoglobulin fusion proteins
TWI793062B (zh) Ｄｌｌ３及ｃｄ３抗體構築體
TWI772258B (zh) Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
KR20210018800A (ko) 암 치료를 위한 항-oxMIF/항-CD3 항체
JP2022516557A (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
JP2024156719A (ja) Ｌａｇ３に結合する治療用分子
JP2017520575A (ja) 二重特異的ヘテロ二量体ダイアボディおよびその使用
KR20220110221A (ko) 항-oxMIF/항-CD3 이중특이적 항체 구축물
KR20230074192A (ko) 인간 cd3 엡실론에 결합하는 신규의 인간 항체
KR20230098334A (ko) Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물
KR20230108288A (ko) 항tspan8-항cd3 이중 특이성 항체 및 항tspan8 항체
KR20230104229A (ko) Cd3에 결합하는 폴리펩티드 구축물
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
CN119546636A (zh) FcRn-结合多肽及其用途
KR20260021753A (ko) Cd3 및 다른 표적을 표적화하는 신규 항체 및 이의 용도
EA051514B1 (ru) Полипептидные конструкции, селективно связывающиеся с cldn6 и cd3

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902